Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 1/20 | 0.39 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.38 |
| ▸ | CCNT1 | O60563 | 7/20 | 0.36 |
| ▸ | KCNH3 | Q9ULD8 | 1/20 | 0.35 |
| ▸ | CCNK | O75909 | 4/20 | 0.35 |
| ▸ | CDK9 | P50750 | 4/20 | 0.35 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.34 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.34 |
| ▸ | KDR | P35968 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL563638 | 0.79 | BRD4 (0.41) | — | |
| SCHEMBL562959 | 0.75 | CNR1 (0.32) | — | |
| SCHEMBL562979 | 0.74 | PLK1 (0.44) | — | |
| SCHEMBL563625 | 0.74 | CCNC (0.44) | — | |
| SCHEMBL3340185 | 0.73 | MAPT (0.38) | — | |
| SCHEMBL562804 | 0.72 | ALDH1A1 (0.41) | — | |
| SCHEMBL562914 | 0.71 | CDK5 (0.48) | — | |
| SCHEMBL17935468 | 0.69 | PTGER4 (0.44) | PTGER4PRKCQ | |
| SCHEMBL563066 | 0.69 | CRHBP (0.44) | — | |
| SCHEMBL562158 | 0.69 | STK17B (0.45) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120035209-A1 | Hydroxy Substituted 1H-Imidazopyridines and Methods | PFIZER INC. (US) | 2012-02-09 | — | — | US | disclosed |
| US-20100152230-A1 | HYDROXY SUBSTITUTED 1H-IMIDAZOPYRIDINES AND METHODS | PFIZER INC. | 2010-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152230-A1 | HYDROXY SUBSTITUTED 1H-IMIDAZOPYRIDINES AND METHODS | IL4, IL2, IL4I1 | PTGER4 179/4885BCAT2 1094/4885CCNT1 2700/4885 |
| US-20120035209-A1 | Hydroxy Substituted 1H-Imidazopyridines and Methods | IL2, IL4, IL4I1 | PTGER4 182/4885BCAT2 1064/4885CCNT1 2681/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.